AXL 的协同失活：治愈卵巢癌的（交叉）之路？
Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?
机构信息
Unité de Traffic Membranaire et Pathogénèse, Institut Pasteur, Paris, France.
出版信息
EMBO Rep. 2018 Aug;19(8). doi: 10.15252/embr.201846492. Epub 2018 Jul 2.
Abstract
Inhibition of the receptor tyrosine kinase AXL, a key molecular driver of ovarian cancer, has recently been highlighted as promising therapeutic strategy. In this issue of , Antony 1 have identified a novel mechanism of inhibition of AXL, wherein the GPI‐anchored tumour suppressor OPCML sequesters AXL into specialised plasma membrane domains where the phosphatase PTPRG is located, therefore facilitating AXL dephosphorylation. This attenuation of AXL signalling has translational implications for the design of synergistic therapies, to target the kinase for this aggressive malignancy.
摘要
AXL 是卵巢癌的关键分子驱动因子，其受体酪氨酸激酶的抑制作用最近被强调为有前途的治疗策略。在本期的 中，Antony 1 等人确定了抑制 AXL 的一种新机制，即 GPI 锚定的肿瘤抑制因子 OPCML 将 AXL 隔离到特殊的质膜域，其中磷酸酶 PTPRG 所在的位置，从而促进 AXL 的去磷酸化。这种 AXL 信号转导的衰减对设计协同治疗具有转化意义，以针对这种侵袭性恶性肿瘤的激酶为靶点。
相似文献
1
Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?AXL 的协同失活：治愈卵巢癌的（交叉）之路？
EMBO Rep. 2018 Aug;19(8). doi: 10.15252/embr.201846492. Epub 2018 Jul 2.
2
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.抑癌基因 OPCML 通过磷酸酶 PTPRG 促进卵巢癌细胞中 AXL 的失活。
EMBO Rep. 2018 Aug;19(8). doi: 10.15252/embr.201745670. Epub 2018 Jun 15.
3
Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma.联合 OPCML 和 AXL 表达作为一种预后标志物，并且 OPCML 增强了胆管癌中的 AXL 抑制剂的作用。
In Vivo. 2022 May-Jun;36(3):1168-1177. doi: 10.21873/invivo.12816.
4
Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.二甲双胍靶向Axl和Tyro3受体酪氨酸激酶以抑制卵巢癌细胞的增殖并克服化疗耐药性。
Int J Oncol. 2015 Jul;47(1):353-60. doi: 10.3892/ijo.2015.3004. Epub 2015 May 12.
5
Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.新型Axl驱动的信号通路和分子特征可表征临床预后较差的高级别卵巢癌患者。
Oncotarget. 2015 Oct 13;6(31):30859-75. doi: 10.18632/oncotarget.5087.
6
Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells.Axl分子靶向作用可对抗卵巢癌细胞的侵袭性，但不能对抗其铂耐药性。
Biochem Pharmacol. 2017 Jul 15;136:40-50. doi: 10.1016/j.bcp.2017.04.002. Epub 2017 Apr 9.
7
Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin.Axl受体酪氨酸激酶与C1-TEN的相互作用，C1-TEN是一种与张力蛋白具有同源性的含新型C1结构域的蛋白质。
Biochem Biophys Res Commun. 2002 Dec 20;299(5):793-800. doi: 10.1016/s0006-291x(02)02718-3.
8
Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.受体酪氨酸激酶 AXL 的治疗性抑制可提高卵巢癌对铂类和紫杉烷类药物的敏感性。
Mol Cancer Ther. 2019 Feb;18(2):389-398. doi: 10.1158/1535-7163.MCT-18-0537. Epub 2018 Nov 26.
9
AXL Downstream Targeting Unravels Synergistic Drug Combinations in Ovarian Carcinoma Cells.AXL下游靶向揭示卵巢癌细胞中的协同药物组合
Anticancer Res. 2019 Jul;39(7):3803-3808. doi: 10.21873/anticanres.13529.
10
AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.AXL 和 CAV-1 在 MTH1 抑制剂 TH1579 对皮肤恶性黑色素瘤的敏感性中发挥作用。
Cell Death Differ. 2020 Jul;27(7):2081-2098. doi: 10.1038/s41418-019-0488-1. Epub 2020 Jan 9.
引用本文的文献
1
The Role of the Tumor Suppressor Gene Protein Tyrosine Phosphatase Gamma in Cancer.肿瘤抑制基因蛋白酪氨酸磷酸酶γ在癌症中的作用
Front Cell Dev Biol. 2022 Jan 5;9:768969. doi: 10.3389/fcell.2021.768969. eCollection 2021.
2
Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies.鸡胚尿囊膜在癌症研究中的应用。
Cells Tissues Organs. 2022;211(2):222-237. doi: 10.1159/000513039. Epub 2021 Mar 29.
本文引用的文献
1
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.抑癌基因 OPCML 通过磷酸酶 PTPRG 促进卵巢癌细胞中 AXL 的失活。
EMBO Rep. 2018 Aug;19(8). doi: 10.15252/embr.201745670. Epub 2018 Jun 15.
2
The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.抑瘤蛋白 OPCML 增强曲妥珠单抗和帕妥珠单抗联合治疗 HER2 阳性卵巢癌和乳腺癌的疗效
Mol Cancer Ther. 2017 Oct;16(10):2246-2256. doi: 10.1158/1535-7163.MCT-17-0081. Epub 2017 Aug 3.
3
AXL-Driven EMT State as a Targetable Conduit in Cancer.AXL 驱动的 EMT 状态作为癌症的一个可靶向途径。
Cancer Res. 2017 Jul 15;77(14):3725-3732. doi: 10.1158/0008-5472.CAN-17-0392. Epub 2017 Jun 30.
4
Targeting the AXL signaling pathway in ovarian cancer.靶向卵巢癌中的AXL信号通路。
Mol Cell Oncol. 2016 Nov 28;4(2):e1263716. doi: 10.1080/23723556.2016.1263716. eCollection 2017.
5
The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.GAS6-AXL信号网络是卵巢癌间充质（Mes）分子亚型特异性治疗靶点。
Sci Signal. 2016 Oct 4;9(448):ra97. doi: 10.1126/scisignal.aaf8175.
6
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.重新思考卵巢癌II：降低高级别浆液性卵巢癌的死亡率
Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019.
7
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.AXL通过激活头颈部和食管鳞状细胞癌中的EGFR/PKC/mTOR轴介导对PI3Kα抑制的抗性。
Cancer Cell. 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010.
8
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.功能基因组学确定了上皮性卵巢癌中具有临床相关性和生长控制途径的五个不同的分子亚型。
EMBO Mol Med. 2013 Jul;5(7):1051-66. doi: 10.1002/emmm.201201823. Epub 2013 May 13.
9
The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.OPCML 肿瘤抑制因子作为细胞表面抑制因子衔接子，在卵巢上皮性癌中负调控受体酪氨酸激酶。
Cancer Discov. 2012 Feb;2(2):156-71. doi: 10.1158/2159-8290.CD-11-0256.
10
Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21.
Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5036-40. doi: 10.1073/pnas.88.11.5036.
Zotero 插件